Literature DB >> 19147501

FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Kentaro Fukushima1, Itaru Matsumura, Sachiko Ezoe, Masahiro Tokunaga, Masato Yasumi, Yusuke Satoh, Hirohiko Shibayama, Hirokazu Tanaka, Atsushi Iwama, Yuzuru Kanakura.   

Abstract

Although leukemogenic tyrosine kinases (LTKs) activate a common set of downstream molecules, the phenotypes of leukemia caused by LTKs are rather distinct. Here we report the molecular mechanism underlying the development of hypereosinophilic syndrome/chronic eosinophilic leukemia by FIP1L1-PDGFRalpha. When introduced into c-Kit(high)Sca-1(+)Lineage(-) cells, FIP1L1-PDGFRalpha conferred cytokine-independent growth on these cells and enhanced their self-renewal, whereas it did not immortalize common myeloid progenitors in in vitro replating assays and transplantation assays. Importantly, FIP1L1-PDGFRalpha but not TEL-PDGFRbeta enhanced the development of Gr-1(+)IL-5Ralpha(+) eosinophil progenitors from c-Kit(high)Sca-1(+)Lineage(-) cells. FIP1L1-PDGFRalpha also promoted eosinophil development from common myeloid progenitors. Furthermore, when expressed in megakaryocyte/erythrocyte progenitors and common lymphoid progenitors, FIP1L1-PDGFRalpha not only inhibited differentiation toward erythroid cells, megakaryocytes, and B-lymphocytes but aberrantly developed eosinophil progenitors from megakaryocyte/erythrocyte progenitors and common lymphoid progenitors. As for the mechanism of FIP1L1-PDGFRalpha-induced eosinophil development, FIP1L1-PDGFRalpha was found to more intensely activate MEK1/2 and p38(MAPK) than TEL-PDGFRbeta. In addition, a MEK1/2 inhibitor and a p38(MAPK) inhibitor suppressed FIP1L1-PDGFRalpha-promoted eosinophil development. Also, reverse transcription-PCR analysis revealed that FIP1L1-PDGFRalpha augmented the expression of C/EBPalpha, GATA-1, and GATA-2, whereas it hardly affected PU.1 expression. In addition, short hairpin RNAs against C/EBPalpha and GATA-2 and GATA-3KRR, which can act as a dominant-negative form over all GATA members, inhibited FIP1L1-PDGFRalpha-induced eosinophil development. Furthermore, FIP1L1-PDGFRalpha and its downstream Ras inhibited PU.1 activity in luciferase assays. Together, these results indicate that FIP1L1-PDGFRalpha enhances eosinophil development by modifying the expression and activity of lineage-specific transcription factors through Ras/MEK and p38(MAPK) cascades.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147501      PMCID: PMC2658066          DOI: 10.1074/jbc.M807489200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Regulation of adipocyte differentiation of bone marrow stromal cells by transcription factor GATA-2.

Authors:  Yoko Okitsu; Shinichiro Takahashi; Naoko Minegishi; Junichi Kameoka; Mitsuo Kaku; Masayuki Yamamoto; Takeshi Sasaki; Hideo Harigae
Journal:  Biochem Biophys Res Commun       Date:  2007-10-15       Impact factor: 3.575

2.  Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis.

Authors:  Miranda Buitenhuis; Liesbeth P Verhagen; Hanneke W M van Deutekom; Anders Castor; Sandra Verploegen; Leo Koenderman; Sten-Eirik W Jacobsen; Paul J Coffer
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

3.  The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

Authors:  Roberta La Starza; Giorgina Specchia; Antonio Cuneo; Donatella Beacci; Chiara Nozzoli; Luigiana Luciano; Anna Aventin; Constantina Sambani; Nicoletta Testoni; Marco Foppoli; Rosangela Invernizzi; Peter Marynen; Massimo F Martelli; Cristina Mecucci
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

4.  Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

Authors:  Jamie Robyn; Steven Lemery; J Philip McCoy; Joseph Kubofcik; Yae-Jean Kim; Svetlana Pack; Thomas B Nutman; Cynthia Dunbar; Amy D Klion
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

5.  Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4.

Authors:  Ryoichi Ono; Masafumi Ihara; Hideaki Nakajima; Katsutoshi Ozaki; Yuki Kataoka-Fujiwara; Tomohiko Taki; Koh-Ichi Nagata; Masaki Inagaki; Nobuaki Yoshida; Toshio Kitamura; Yasuhide Hayashi; Makoto Kinoshita; Tetsuya Nosaka
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

6.  Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.

Authors:  Mathieu Capovilla; Jean-Michel Cayuela; Chrystèle Bilhou-Nabera; Claude Gardin; Remi Letestu; Fanny Baran-Marzak; Pierre Fenaux; Antoine Martin
Journal:  Eur J Haematol       Date:  2007-11-19       Impact factor: 2.997

7.  Identification of a novel distal enhancer in human adiponectin gene.

Authors:  Katsumori Segawa; Morihiro Matsuda; Atsunori Fukuhara; Kentaro Morita; Yosuke Okuno; Ryutaro Komuro; Iichiro Shimomura
Journal:  J Endocrinol       Date:  2008-10-17       Impact factor: 4.286

8.  Activation of mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment.

Authors:  Chia-Lin Hsu; Kazu Kikuchi; Motonari Kondo
Journal:  Blood       Date:  2007-05-29       Impact factor: 22.113

9.  The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.

Authors:  Elizabeth H Stover; Jing Chen; Benjamin H Lee; Jan Cools; Elizabeth McDowell; Jennifer Adelsperger; Dana Cullen; Allison Coburn; Sandra A Moore; Rachel Okabe; Doriano Fabbro; Paul W Manley; James D Griffin; D Gary Gilliland
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

10.  Identification of eosinophil lineage-committed progenitors in the murine bone marrow.

Authors:  Hiromi Iwasaki; Shin-ichi Mizuno; Robin Mayfield; Hirokazu Shigematsu; Yojiro Arinobu; Brian Seed; Michael F Gurish; Kiyoshi Takatsu; Koichi Akashi
Journal:  J Exp Med       Date:  2005-06-13       Impact factor: 14.307

View more
  10 in total

1.  ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.

Authors:  Carmen P Montano-Almendras; Ahmed Essaghir; Hélène Schoemans; Inci Varis; Laura A Noël; Amélie I Velghe; Dominique Latinne; Laurent Knoops; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Bridges between Cell Cycle Regulation and Self-Renewal Maintenance.

Authors:  Patrick Viatour
Journal:  Genes Cancer       Date:  2012-11

3.  Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis.

Authors:  Jean-Baptiste Demoulin; Carmen P Montano-Almendras
Journal:  Am J Blood Res       Date:  2012-01-01

4.  BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.

Authors:  Masahiro Tokunaga; Sachiko Ezoe; Hirokazu Tanaka; Yusuke Satoh; Kentaro Fukushima; Keiko Matsui; Masaru Shibata; Akira Tanimura; Kenji Oritani; Itaru Matsumura; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

5.  Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.

Authors:  Bin Li; Guangsen Zhang; Cui Li; Dan He; Xinying Li; Chunfang Zhang; Faqing Tang; Xiyun Deng; Jingchen Lu; Youhong Tang; Ruijuan Li; Zhuchu Chen; Chaojun Duan
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

6.  The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.

Authors:  Yingying Shen; Xiaoke Shi; Jingxuan Pan
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

Review 7.  Targeting the PDGF signaling pathway in tumor treatment.

Authors:  Carl-Henrik Heldin
Journal:  Cell Commun Signal       Date:  2013-12-20       Impact factor: 5.712

8.  Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.

Authors:  Violaine Havelange; Jean-Baptiste Demoulin
Journal:  J Blood Med       Date:  2013-08-09

9.  Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities.

Authors:  Makoto Ibata; Junko Iwasaki; Yoichiro Fujioka; Koji Nakagawa; Stephanie Darmanin; Masahiro Onozawa; Daigo Hashimoto; Yusuke Ohba; Shigetsugu Hatakeyama; Takanori Teshima; Takeshi Kondo
Journal:  Cancer Sci       Date:  2017-02       Impact factor: 6.716

10.  Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.

Authors:  Bin Li; Guangsen Zhang; Cui Li; Ruijuan Li; Jingchen Lu; Zhengxi He; Quan Wang; Zhenzi Peng; Jun Wang; Yeping Dong; Chunfang Zhang; Jie Qiong Tan; Nacef Bahri; Yuexiang Wang; Chaojun Duan
Journal:  Oncotarget       Date:  2016-08-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.